FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)
-
-
-
-
-
-
-
Cogent Biosciences submits drug application for GIST treatment
-
-
-
-
-
-
-
Cogent Biosciences gets FDA breakthrough therapy status for GIST drug combo
-
-
-
-
-
-
-
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
-
-
-
-
-
-
-
Cogent Biosciences presents full SUMMIT trial results for bezuclastinib
-
-
-
-
-
-
-
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
-
-
-
-
-
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
325,891 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

